Accord Healthcare to offer generic schizophrenia, bipolar depression drug

A generic pharmaceutical company announced the availability of a schizophrenia and bipolar depression treatment, according to a press release.

Accord Healthcare will offer lurasidone hydrochloride, which is AB-rated to Sunovion Pharma's Latuda, in doses of 20 mg, 40 mg, 60 mg, 80 mg and 120 mg, with 30 tablets in each bottle.

According to the release, lurasidone is an atypical antipsychotic that is a first-line treatment for schizophrenia. It is approved by the FDA in the treatment of bipolar depression.

“By offering lurasidone, we hope to reduce the burden of costs of long-term treatment for individuals who can benefit from this medication,” Divya Verma, vice president of marketing and portfolio at Accord Healthcare, said in the release. “A generic option in mental health treatment provides more accessible health care to those who are in need.”